Closing the women’s health gap: Biopharma’s untapped opportunity
Most top pharma companies derive more than 60 percent of their revenue from therapies for diseases that affect women uniquely, differently, or disproportionately, putting them in a prime position to close the sex- and gender-based health gap.
Most top pharma companies derive more than 60 percent of their revenue from therapies for diseases that affect women uniquely, differently, or disproportionately, putting them in a prime position to close the sex- and gender-based health gap.
![Is this Constructive Dismissal? [closed]](https://cdn.sstatic.net/Sites/workplace/Img/apple-touch-icon@2.png?v=d39b333f5c58)
